NCT04918030Completed
STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（STAGED）
STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease （STAGED）
Source: ClinicalTrials.gov · Last updated 12 Dec 2025
Brief summary (registry, in English)
An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the difference in major adverse cardiac event (MACE) between Early staged PCI versus Late staged PCI groups among patients with ST-segment elevated myocardial infarction （STEMI and multi-vessel Disease（MVD) who underwent primary PCI using DES for culprit lesions. Background: In patients with STEMI with MVD who underwent primary PCI, complete revascularization for non-culprit lesions has proved to reduce the risk of cardiovascular death and myocardial infarction. However, the ideal timing point for staged PCI for nonculprit lesions remains uncertain.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1586 (actual)
- First submitted
- 24 May 2021
- Start date
- 11 Feb 2021
- Primary completion date
- 1 Feb 2025
- Lead sponsor
- Xiamen Cardiovascular Hospital, Xiamen University
- Diseases
- Coronary artery disease
- NCT number
- NCT04918030
What you commit to
- Study type: Interventional
- Participants enrolled: 1586
- From 11 Feb 2021 to the primary completion date, 1 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous documented allergic reaction to drug and device of this study;
- Planned major surgery within 6 weeks in which impact DAPT;
Other illness
- Cardiac shock, multiple organ failure, cerebral hemorrhage, severe aortic stenosis and myocardial infarction complications(cardiac rupture, ventricular septal rupture and papillary muscle rupture);
- Any condition likely to interfere with study processes including follow-up visits or increase of risk accessed by researcher.
Age
- Age \<18 yr and \>80 yr;
Other
- Killip classification \>3, cardiognic shock, shore-infarction of culprit artery after emergency PCI in 24 hours;
- Participation in another clinical study, interfering with this protocol Uncertain;
- Life expectancy \< 1 year;
Who the study is looking for
- Provision of informed consent prior to any study specific procedures;
- Established indication to PPCI according to the guidelines of American Heart Association and American College of Cardiology;
- Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) with MVD after successful revascularization of the culprit artery;
- De novo coronary lesion,
- TIMI Flow 3 ( Cases with TIMI flow 2 need to perform angiographic again in 24h ensured TIMI flow 3 for enrolling case )after revascularization of the culprit artery, residual stenosis ≤20% and no coronary dissection greater than or equal to type C leading to (threatening) vessel closure.
- At least one non-culprit coronary stenosis ≥ 80% and accompanied by QFR ≤0.8 in a vessel with a lumen diameter ≥2.5;
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiamen Cardiovascular Hospital Xiamen University Coordinator of this site? Confirm its status | Xiamen | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.